ArticleCurrent infectious disease reports2015
Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?
Article in Current infectious disease reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Pseudomonas aeruginosa senses and responds to epithelial potassium flux via Kdp operon to promote biofilm.PLoS pathogens · 2024Article
- Clinical and microbiological evaluation of ventilator-associated pneumonia in an intensive care unit in Vietnam.Infection prevention in practice · 2023Article
- Infection in systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a potential key to improve outcomes.Clinical rheumatology · 2023Article
- Use of polymyxin B with different administration methods in the critically ill patients with ventilation associated pneumonia: a single-center experience.Frontiers in pharmacology · 2023Article
- Clinical Efficacy andFrontiers in pharmacology · 2022Article
- Retrospective Assessment of Ventilator-Associated Pneumonias due toSisli Etfal Hastanesi tip bulteni · 2021Article
- Ventilator-associated pneumonia in adults: a narrative review.Intensive care medicine · 2020Review
- Emergence and molecular characterization of multidrug-resistantInfection and drug resistance · 2019Article
- Comparison of Intravenous Ampicillin-sulbactam Plus Nebulized Colistin with Intravenous Colistin Plus Nebulized Colistin in Treatment of Ventilator Associated Pneumonia Caused by Multi Drug ResistantIranian journal of pharmaceutical research : IJPR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.
Identifiers
26092246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.